Federica Sora'
professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Chronic myeloid leukemia (CML) patients who have experienced failure and/or intolerance to multiple lines of treatment have limited therapeutic possibilities. Asciminib is a first‐in‐class tyrosine kinase inhibitor (TKI) that inhibits the ABL Myristoyl Pocket (STAMP or Specifically Targeting the ABL Myristoyl Pocket) within the BCR::ABL1 oncoprotein. This retrospective Italian analysis reports the efficacy and safety outcomes of asciminib in treating 77 CML patients in chronic phase (CML‐CP) within a compassionate use setting. Patients were heavily pretreated with a median of 3 TKIs (55.8% had prior ponatinib exposure). Overall, 57.1% and 42.9% patients switched to asciminib because of resistance and intolerance, respectively. Asciminib maintained or improved molecular responses (MRs) in most patients: as best response, 41 patients (53%) achieved a MR3 or better, with 25 patients (32.5%) reaching deep molecular response (DMR). Greater percentages of intolerant patients achieved MR compared with resistant patients, although the probability of reaching at least a MR3 was not significant between the two groups ( p = 0.116). Patients with the T315I mutation responded to asciminib, while ponatinib pre‐treated patients showed lower MR improvements compared to naïve patients and had a lower probability to reach a MR3 versus naïve patients ( p = 0.0262). These results highlight asciminib remarkable tolerability and efficacy in real‐world CML‐CP patient population, including heavily pretreated patients, those intolerant and resistant to previous TKIs, and presenting several comorbidities. Trail Registration The identification code for the MAP is CABL001AIT01M.
Year:
2025
Disease burden is a critical determinant of outcomes in CAR‐T therapy for B‐cell lymphomas, and one of the most widely used techniques for its assessment is Total Metabolic Tumor Volume (TMTV) measured via [ 18 F]FDG PET/CT. Biological parameters may further refine the risk profile. We analyzed baseline [ 18 F]FDG PET/CT scans from 40 patients treated with CAR‐T, using an AI‐based automated segmentation algorithm to determine TMTV. Our analysis identified that a baseline TMTV greater than 48.4 cm³ and elevated LDH independently predicted progression‐free survival (PFS) after CAR‐T therapy (HR 4.28, p = 0.007, and HR 8.20, p < 0.001, respectively). We then proposed a 0‐to‐2 risk score, assigning one point each for elevated TMTV and elevated LDH. All patients with a score of two experienced a PFS of less than 90 days following CAR‐T infusion. Among the remaining patients, those with 0 points versus 1 point demonstrated a 3‐month PFS of 100% versus 85%, a 6‐month PFS of 92% versus 53%, and a 12‐month PFS of 83% versus 53%, respectively. Importantly, patients with high baseline TMTV who achieved a TMTV reduction to less than 1.99 cm³ by day 30 had a PFS of 66%, significantly better compared to those who did not achieve this reduction. AI‐guided TMTV assessment, combined with LDH levels, provides a rapid and sensitive method for risk stratification at the bedside, which could help optimize patient management prior to CAR‐T therapy.
Year:
2024
This real-world prospective observational study across 21 Italian centers ( CART-SIE ) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) and neurotoxicity (9.9% vs. 32.2%, P P = 0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs. 22.7%, P = 0.0059). Differences in overall survival and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, P Significance: The findings of this study on 485 patients with relapsed/refractory large B-cell lymphoma treated with commercial axi-cel and tisa-cel indicate axi-cel’s superior PFS after propensity score weighting. The predictive utility of CAR-HEMATOTOX in assessing not only toxicity but also outcomes across both CAR T-cell products may guide future risk-stratified management strategies.
Year:
2024
This real-world prospective observational study across 21 Italian centers ( CART-SIE ) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 patients with relapsed/refractory large B-cell lymphoma with baseline characteristics matched by stabilized inverse propensity score weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs. 89.3%, P = 0.0017) and neurotoxicity (9.9% vs. 32.2%, P P = 0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs. 22.7%, P = 0.0059). Differences in overall survival and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, P Significance: The findings of this study on 485 patients with relapsed/refractory large B-cell lymphoma treated with commercial axi-cel and tisa-cel indicate axi-cel’s superior PFS after propensity score weighting. The predictive utility of CAR-HEMATOTOX in assessing not only toxicity but also outcomes across both CAR T-cell products may guide future risk-stratified management strategies.
Year:
2024
Collaborators (14)
Armando Santoro
Professore
Humanitas University
Federica Cavallo
University of Turin
Massimo Massaia
Associate Professor of Hematology
Università degli Studi di Torino
Paolo Corradini
Full Professor of Hematology
University of Milan
PIER LUIGI ZINZANI
University of Bologna
Mauro Krampera
Docenti di ruolo di Ia fascia
University of Verona
Luca Arcaini
Director of Division of Hematology
Fondazione IRCCS Policlinico San Matteo
Domenico Russo
University of Brescia
Marco LADETTO
Associate Professor
Università degli Studi del Piemonte Orientale
Patrizia Chiusolo
Università Cattolica del Sacro Cuore
Massimo Martino
Director Stem Cell Transplant Program
Azienda ospedaliera "Bianchi-Melacrino-Morelli"
Silva Ljevar
Fondazione IRCCS Istituto Nazionale dei Tumori
Massimo Breccia
-
ANNALISA CHIAPPELLA
Fondazione IRCCS Istituto Nazionale dei Tumori
Make your next move.
Prepare your application
Review drafts before you send them.